ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1960

Initiation of Tumor Necrosis Factor Alpha (TNFα) Antagonists and Risk of Fractures in Patients with Selected Rheumatic and Autoimmune Diseases

Vivian K. Kawai1, Carlos Grijalva2, Patrick Arbogast2, Jeffrey R. Curtis3, Daniel H. Solomon4, Elizabeth S. Delzell5, Lang Chen6, Lisa Herrinton7, Liyan Liu7, Edward F. Mitchell Jr.2, C. Michael Stein8 and Marie Griffin2, 1Vanderbilt University, Nashville, TN, 2Preventive Medicine, Vanderbilt University, Nashville, TN, 3Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 4Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, 5Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 6Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 7Division of Research, Kaiser Permanente, Oakland, CA, 8School of Medicine, Division of Clinical Pharmacology, Vanderbilt Medical Center, Nashville, TN

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Anti-TNF therapy and fractures

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoporosis and Metabolic Bone Disease

Session Type: Abstract Submissions (ACR)

Initiation of Tumor Necrosis Factor Alpha (TNFα) antagonists and risk of fractures in patients with rheumatoid arthritis (RA)

Background/Purpose:  Inflammation mediates bone resorption, in part through TNFα.  In experimental models TNFα antagonists reduce inflammation-mediated bone resorption; however, the effect of this class of drugs on fracture risk in patients is unknown.  We tested the hypothesis that initiation of TNFα antagonists reduced the risk of fractures compared to nonbiologic comparators in patients with RA.

Methods:  Using four large administrative databases we assembled a retrospective cohort of patients with RA from 1998 to 2005 enrolled in Tennessee’s Medicaid Program (TennCare), Kaiser Permanente Northern California (KPNC), Pennsylvania Pharmaceutical Assistance Contract for the Elderly (PACE), and multi-State Medicaid programs (MAX) and identified patients who initiated either a TNFα antagonist (n=20,814) or a non biologic disease modifying anti-rheumatic drug (DMARD): hydroxychloroquine (HCQ), sulfazalasine (SSZ) and/or leflunomide (LEF) (n=8,964).  We used baseline covariate data to calculate propensity scores (PS) to match treatment groups, and Cox regression to calculate hazard ratios (HRs) and 95% confidence intervals (95% CIs).  We compared the risk of the first fracture (hip, radius/ulna, humerus, or pelvic); first hip fracture; and first clinical vertebral fracture between PS-matched cohorts of new users of TNFα antagonists and non biologic DMARDs.

Results: We identified 9,020 new PS matched episodes of TNFα antagonist and non biologic DMARD use.  The risk of fractures was similar between new users of TNFα antagonists and non biologic DMARDs: HR:1.17, 95%CI [0.91-1.51] for combined fracture outcome (Figure 1); HR:0.87, 95%CI [0.60-1.27] for hip fracture (Figure 2); and HR:0.71, 95%CI [0.43-1.19] for clinical vertebral fracture (Figure 3).  The risk of the combined fracture outcome was associated with an average daily dose of prednisone equivalents >10 mg/day at baseline compared with no glucocorticoid (HR: 1.54, 95%CI [1.03, 2.30]).

Conclusion: The risk of fracture did not differ between new users of TNFα antagonists and non biologic DMARDs in patients with RA.  The use of >10mg/day of prednisone equivalents at baseline increased the fracture risk.


Disclosure:

V. K. Kawai,
None;

C. Grijalva,
None;

P. Arbogast,
None;

J. R. Curtis,

Roche/Genetech, UCB, Centocor, CORRONA, Amgen Pfizer, BMS, Crescendo, Abbott,

5,

Roche/Genetech, UCB, Centocor, CORRONA, Amgen Pfizer, BMS, Crescendo, Abbott,

2;

D. H. Solomon,

Amgen & Lilly,

2,

Corrona,

5,

Pfizer Inc,

9;

E. S. Delzell,

Amgen Inc,

2;

L. Chen,
None;

L. Herrinton,

Procter and Gamble, Centocor,Genentech,

2;

L. Liu,
None;

E. F. Mitchell Jr.,
None;

C. M. Stein,
None;

M. Griffin,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/initiation-of-tumor-necrosis-factor-alpha-tnf%ce%b1-antagonists-and-risk-of-fractures-in-patients-with-selected-rheumatic-and-autoimmune-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology